Education
About Us
Working with TipRanks
Follow Us
Eyenovia Inc (EYEN)
NASDAQ:EYEN
EYEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $124.80
Previous CloseN/A
Volume25.52M
Average Volume (3M)8.60M
Market Cap
$31.36M
Enterprise Value$4.38B
Total Cash (Recent Filing)$2.12M
Total Debt (Recent Filing)$11.24M
Price to Earnings (P/E)―
Beta2.84
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding2,882,808
10 Day Avg. Volume10,922,639
30 Day Avg. Volume8,601,987
Financial Highlights & Ratios
PEG Ratio-2.35
Price to Book (P/B)254.60
Price to Sales (P/S)0.00
P/FCF Ratio-168.89
Enterprise Value/Market Cap139.49
Enterprise Value/Revenue33.82K
Enterprise Value/Gross Profit-1.02K
Enterprise Value/Ebitda-30.65
Forecast
1Y Price Target
$2.00Price Target Upside-81.62% Downside
Rating ConsensusHold
Number of Analyst Covering0
Eyenovia News
PremiumCompany Announcements
Eyenovia Launches Co-Branded Hyperliquid Validator with Kinetiq
PremiumCompany Announcements
Eyenovia Announces $50M Private Placement and New CIO
PremiumCompany Announcements
Eyenovia Amends Loan Agreement with Avenue CapitalBulls Say, Bears Say
Bulls Say
Merger OpportunitiesThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Technology LicensingBetaliq’s EyeSol delivery technology has been licensed for FDA-approved topical eye drops MEIBO and VEVYE in the treatment of dry eye disease.
Bears Say
Clinical Trial ChallengesThe Phase 3 CHAPERONE trial using the Optejet optimized spray dispenser for delivering MicroPine atropine for reduction of pediatric progressive myopia was discontinued.
Revenue RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
Ownership Overview
11.34% Insiders
2.29% Mutual Funds
9.00% Other Institutional Investors
75.71% Public Companies and Individual Investors
EYEN FAQ
What was Eyenovia Inc’s price range in the past 12 months?
Eyenovia Inc lowest stock price was $0.85 and its highest was $124.80 in the past 12 months.
What is Eyenovia Inc’s market cap?
Eyenovia Inc’s market cap is $31.36M.
When is Eyenovia Inc’s upcoming earnings report date?
Eyenovia Inc’s upcoming earnings report date is Aug 06, 2025 which is in 38 days.
How were Eyenovia Inc’s earnings last quarter?
Eyenovia Inc released its earnings results on May 19, 2025. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.59.
Is Eyenovia Inc overvalued?
According to Wall Street analysts Eyenovia Inc’s price is currently Overvalued.
Does Eyenovia Inc pay dividends?
Eyenovia Inc does not currently pay dividends.
What is Eyenovia Inc’s EPS estimate?
Eyenovia Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eyenovia Inc have?
Eyenovia Inc has 2,882,808 shares outstanding.
What happened to Eyenovia Inc’s price movement after its last earnings report?
Eyenovia Inc reported an EPS of -$1.59 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 47.788%.
Which hedge fund is a major shareholder of Eyenovia Inc?
Currently, no hedge funds are holding shares in EYEN
Company Description
Eyenovia Inc
Eyenovia, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative ophthalmic therapies. The company operates in the biotechnology and pharmaceuticals sectors, with a core focus on creating microdosed medications for eye care using its proprietary Optejet dispenser. Eyenovia's pipeline includes therapies for myopia progression, presbyopia, and pupil dilation.